KOSPIBiotech & Pharma000520

Samil Pharmaceutical

₩6,660▼ 0.89%2026-11-18 close
Market Cap
₩144.5B
Turnover
₩300M
Volume
50K
Shares out.
21.7M
PER
—
PBR
1.3×
EPS
-₩1,695
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Losses Narrow as Vietnam Plant Becomes the Key Variable

Samil Pharmaceutical swung to an operating loss in 2025, and its quarterly operating losses have narrowed from the first quarter of 2026 through the third quarter, with Vietnam plant certification and the resumed sales of Afilibu as the key variables for a recovery.

  1. 1

    Revenue in 2025 was KRW 210.3 billion, down 4.3% from the prior year, and 2024 (KRW 219.7 billion) was the largest year in the 2022–2025 period.

  2. 2

    The operating loss in 2025 was KRW 22.2 billion, a swing into deficit, and the net loss attributable to controlling shareholders of KRW 34.7 billion marks a second consecutive year of losses after 2024.

  3. 3

    Quarterly operating losses narrowed from the first quarter through the third quarter of 2026 compared with the preceding quarter, and the third-quarter operating loss was KRW 3.19 billion.

  4. 4

    The recovery variables are the resumed sales of Afilibu, KGMP certification of the Vietnam CMO plant targeted for the second half of 2026, and ongoing talks on eye-drop CMO contracts.

  5. 5

    The FDA decision on lorecivivint and the certification schedule for the Vietnam plant are the key events that will shape the earnings path.

02

Business structure

Samil Pharmaceutical is a small-to-mid-sized pharmaceutical company founded in 1947 that focuses on eye diseases. As of 2024, its ophthalmology and CNS (central nervous system) sales divisions led growth.

Most revenue comes from the pharmaceutical segment, and at the end of 2025 the pharmaceutical share was 97.83% of revenue and other revenue was 2.17%. Pharmaceutical revenue splits between in-house developed and manufactured products and goods imported for resale.

In the first quarter of 2025, in-house product sales were KRW 31.0 billion and goods sales were KRW 20.3 billion. Key products include the glaucoma drug Monoprost, the depression drug Zolofut, and dry-eye products Hyabak and Lestasis.

In 2024, cumulative ophthalmology division sales reached KRW 67.2 billion, up 34.4% year on year, and the CNS division reached KRW 36.5 billion, up 30.4%. Afilibu, an Eylea biosimilar launched in May 2024, saw sales halted in 2025 and resumed in 2026.

Production is split between the Ansan plant and the Vietnam plant, which is aimed at contract manufacturing (CMO) and contract development and manufacturing (CDMO) for eye drops.

At CPHI Milan 2026 in October 2026, the company said it was in talks with eye-care pharmaceutical firms in Europe, Japan and North America on eye-drop CMO supply.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩51.2B-₩5.2B−10.1%
2025Q4₩53B-₩8.6B−16.2%
2026Q1₩52.5B-₩8.4B−15.9%
2026Q2₩50.6B-₩6.3B−12.5%
2026Q3₩51.4B-₩3.2B−6.2%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩179.7B₩4B-₩28,287,0102.2%0.0%183.5%
2023₩196.3B₩6.5B₩1.7B3.3%1.3%190.0%
2024₩219.7B₩100M-₩5.6B0.1%−3.2%124.3%
2025₩210.3B-₩22.2B-₩34.7B−10.6%−26.0%178.9%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

Annual results show diverging trends in scale and profitability. Revenue rose from KRW 179.7 billion in 2022 to KRW 196.3 billion in 2023 (up 9.3% year on year) and KRW 219.7 billion in 2024 (up 11.9%), then fell to KRW 210.3 billion in 2025 (down 4.3%).

Operating profit was KRW 4.02 billion in 2022 and KRW 6.47 billion in 2023 (up 61.1%), but dropped to KRW 113 million in 2024 (down 98.3%). For 2024, the company attributed the drop to higher personnel and operating costs at the Vietnam subsidiary as it prepared for commercial production.

In 2025 the company swung to an operating loss of KRW 22.2 billion, with an operating margin of -10.6%.

Net income attributable to controlling shareholders was a loss of KRW 28.29 million in 2022, a profit of KRW 1.66 billion in 2023 (a swing into profit), a loss of KRW 5.63 billion in 2024 (a swing into loss) and a loss of KRW 34.7 billion in 2025 (losses continued and widened).

Losses have occurred in 2024 and 2025 for two consecutive years, and net income including non-controlling interests followed the same pattern.

SK Securities cited the 2025 loss widening to the suspension of Afilibu sales amid a patent dispute, about KRW 3 billion in one-time clinical costs, and lost sales tied to delayed GMP certification of the Vietnam CMO plant.

Operating cash flow was KRW 4.15 billion in 2022, KRW 11.7 billion in 2023, KRW 2.59 billion in 2024 and KRW 568 million in 2025.

Quarterly, the operating loss widened to KRW 5.15 billion in the third quarter of 2025 and KRW 8.57 billion in the fourth quarter, then narrowed to KRW 8.38 billion, KRW 6.33 billion and KRW 3.19 billion in the first through third quarters of 2026, each narrowing versus the prior quarter.

Third-quarter 2026 revenue was KRW 51.4 billion, up 0.5% year on year, and the net loss attributable to controlling shareholders was KRW 6.4 billion, down from KRW 7.93 billion a year earlier.

The net loss attributable to controlling shareholders over the last four quarters (fourth quarter 2025 to third quarter 2026) totaled KRW 36.1 billion. For January through September 2026, revenue was KRW 154.57 billion (down 1.7% year on year) and operating loss was KRW 17.9 billion (widened year on year).

The company attributed the cumulative operating loss mainly to selling and administrative costs at the Vietnam subsidiary, including KRW 4.8 billion in depreciation and KRW 1.7 billion in repairs. These figures come from the quarterly report filed on November 16, 2026.

05

Industry analysis

Samil Pharmaceutical's end demand splits between the ophthalmology prescription market and contract production for biosimilars and eye drops. On the biosimilar side, Afilibu's sales were halted by a patent dispute and later resumed, which shows how patent outcomes can directly move product revenue.

Goods sales depend on purchasing externally sourced products. In the first quarter of 2025 goods sales were KRW 20.3 billion, down 12.0% year on year, while goods purchases rose 12.0% to KRW 27.8 billion, which weighed on profitability.

On the CMO side, SK Securities cited an annual production capacity of about KRW 280 billion for the Vietnam plant, and also mentioned KRW 600 billion at full utilization. That is a brokerage estimate, and actual utilization will depend on certification and order pace.

Because the plant is dedicated to eye drops, its product scope is limited, and the company has named eye-care pharmaceutical firms in Europe, Japan and North America as its main counterparties.

The company also said in October 2026 that it was discussing exports of finished products made in Ansan and Vietnam with partners in the Middle East, Asia and Europe, and that the Asian export talks for Limadin tablets were becoming concrete.

06

Outlook

In a February 2026 report, SK Securities projected Samil Pharmaceutical's standalone revenue for 2026 at KRW 239.4 billion (up 13.8% year on year) and operating profit at KRW 11.3 billion.

Because that estimate is on a standalone basis, it is hard to compare directly with consolidated revenue of KRW 154.57 billion for January through September 2026.

The same report said first-month sales after Afilibu's resumption exceeded KRW 1.5 billion and that a full-year effect could restore annual sales of roughly KRW 20 billion in 2026.

The KGMP certification target for the Vietnam plant was listed for the second half of 2026 in the first-quarter 2026 report, while US cGMP and EU-GMP were listed for 2027. The KGMP target had already slipped once, from 2025 to the first half of 2026.

Lorecivivint, a knee osteoarthritis candidate for which the company holds Korean exclusive rights, had an NDA submitted to the US FDA, and SK Securities expected an approval decision within the fourth quarter of 2026.

The same report presented, under conservative assumptions, potential annual revenue of KRW 200 billion to KRW 600 billion if approval is secured. At CPHI Milan 2026 the company said it had completed term sheets with some overseas pharmaceutical firms and expected additional eye-drop CMO contracts within the year.

It also said an export contract for Limadin tablets in Asia could come as early as this year. The next periodic report, the 2026 annual report, will confirm full-year results and the operating status of the Vietnam plant.

07

Valuation

PER
—
PBR
1.3×
ROE
-28.6%
EPS
-₩1,695
BPS
₩5,106
Dividend per share
₩0

The price-to-earnings ratio cannot be calculated because the company has posted net losses over the last four quarters. Because earnings-based multiples are hard to compare, asset-based measures are the usual reference point.

Total equity at the end of 2025 was KRW 133.3 billion, and equity attributable to controlling shareholders was the same KRW 133.3 billion. The price-to-book ratio sits above 1x, which means the market price carries a premium over book value.

The debt ratio rose from 124.3% in 2024 to 178.9% in 2025, with total liabilities of KRW 238.3 billion. Dividend yield is close to nil, so comparisons on a dividend basis are limited. While the losses continue, asset-based measures and the debt structure remain the core reference for valuation.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Quarterly losses keep narrowing

Quarterly operating losses narrowed from the first quarter through the third quarter of 2026 compared with the prior quarter, and the third-quarter loss was KRW 3.19 billion. The third-quarter net loss attributable to controlling shareholders was KRW 6.4 billion, smaller than KRW 7.93 billion a year earlier. The losses continue, but their size has narrowed in each quarter.

Afilibu sales resume with a standalone outlook

SK Securities pointed out that first-month sales after Afilibu's resumption exceeded KRW 1.5 billion. The same report presented a 2026 standalone revenue estimate of KRW 239.4 billion and operating profit of KRW 11.3 billion. This is a February 2026 brokerage estimate and reads as the brokerage's recovery scenario.

Vietnam CMO and export talks expand

The counterparties are eye-care pharmaceutical firms in Europe, Japan and North America, and whether these talks turn into actual contract manufacturing agreements is the next point to check. It said term sheets had been completed with some overseas firms and it expected additional CMO contracts within the year. Export talks for Limadin tablets in Asia have also become more concrete.

09

Bear factors

Two consecutive years of losses

The net loss attributable to controlling shareholders was KRW 5.63 billion in 2024 and KRW 34.7 billion in 2025, two consecutive years of losses. The 2025 loss continued and widened. The cumulative operating loss for January through September 2026 of KRW 17.9 billion was larger than a year earlier.

Certification delays and fixed costs at Vietnam

The KGMP certification target for the Vietnam plant moved from 2025 to the first half of 2026 and then to the second half of 2026. Over the same period, depreciation and repair costs at the Vietnam subsidiary were recorded in selling and administrative expenses and enlarged the cumulative operating loss. Fixed costs accrue before certification, so losses continue ahead of full operation.

Revenue decline and goods purchase pressure

Revenue in 2025 was KRW 210.3 billion, down 4.3% from the prior year, and cumulative January–September 2026 revenue fell 1.7% year on year. In the first quarter of 2025, goods sales fell 12.0% while goods purchases rose 12.0%. The rise in purchases has pressured profitability.

10

Risk factors

Regulatory and certification timing

The KGMP certification for the Vietnam plant slipped from a 2025 target to the first half of 2026 and then to the second half of 2026. US cGMP and EU-GMP certifications are set for 2027, so revenue from US and European CMO contracts could be pushed back accordingly. Depreciation and repair costs continue during delays, which adds to the cumulative operating loss.

Product and patent concentration

Afilibu's sales were once halted by a patent dispute, so a legal variable in one product can move total revenue. Goods sales depend on externally sourced products, so changes in purchasing terms feed directly into profitability. If the FDA decision on lorecivivint is delayed or not approved, expectations for the pipeline would weaken.

Financial structure

At the end of 2025, total liabilities were KRW 238.3 billion against total equity of KRW 133.3 billion, so liabilities exceed equity. The debt ratio rose from 124.3% in 2024 to 178.9% in 2025.

Operating cash flow fell from KRW 4.15 billion in 2022 to KRW 568 million in 2025, which weakens internal cash generation while losses continue.

11

What to watch next

  1. By end of December 2026

    FDA decision on lorecivivint. The outcome would change the value of the Korean exclusive rights and the direction of pipeline momentum.

  2. Second half of 2026 (by end of December)

    Whether the Vietnam plant obtains KGMP certification. Full CMO production and revenue recognition depend on certification, making it a precondition for commercial operation.

  3. By end of December 2026

    Whether additional eye-drop CMO contracts and the Limadin tablets export contract for Asia are signed. The company expects them within the year, and signed contracts would make utilization assumptions at the Vietnam plant more concrete.

  4. By end of March 2027

    Filing of the 2026 annual report. Full-year results are confirmed, showing the 2026 operating loss and whether the deficit trend since 2024 continued.

  5. Mid-May 2027

    The first-quarter 2027 quarterly report. It will show whether the 2026 narrowing of quarterly losses continued and how much Vietnam subsidiary costs weighed on the quarter.

12

Overall view

Samil Pharmaceutical's revenue scale has grown since 2022, but revenue fell 4.3% in 2025 and the company swung to an operating loss of KRW 22.2 billion. In 2025, the halt of Afilibu sales, one-time clinical costs and the delayed Vietnam plant certification combined to widen losses.

Quarterly operating losses narrowed from the first quarter through the third quarter of 2026, yet the cumulative operating loss for January–September 2026 was larger than a year earlier.

Bullish factors include the resumed Afilibu sales, expanding Vietnam CMO talks and the possibility of an FDA decision on lorecivivint. Bearish factors include two consecutive years of losses, a rising debt ratio, certification delays with fixed costs at Vietnam, and pressure from higher goods purchases.

These factors coexist, and the direction will be clearer from the 2026 annual report and the first-quarter 2027 results. Because losses rule out earnings-based comparisons, valuation is read mainly through asset-based measures.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. ssl.pstatic.net
  2. comp.fnguide.com
  3. startuptoday.co.kr
  4. medipana.com
  5. medipana.com
  6. pharm.edaily.co.kr
  7. hanaw.com
  8. hitnews.co.kr
  9. medifonews.com
  10. medicopharma.co.kr
  11. vegannews.co.kr
  12. dailypharm.com
  13. newsworker.co.kr
  14. thefairnews.co.kr
  15. startuptoday.co.kr
  16. thebell.co.kr
  17. insightkorea.co.kr
  18. thebionews.net

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis